0013 GMT - Nufarm's annual earnings could positively surprise, signals Morgans. Nufarm pointed to 1H underlying Ebitda of A$239 million-A$244 million, up 17% on a year ago at the midpoint of the range. Nufarm has benefited from higher Crop Protection margins, growth in Hybrid Seeds and a stronger performance from its emerging Omega-3 and bioenergy platforms. It's also targeting an additional A$50 million of cost savings. "Given the appreciation in active ingredient and fish oil prices, Nufarm's previous FY26 guidance could prove to be conservative," analyst Belinda Moore says. Morgans keeps a buy call on Nufarm, partly on expectations that the crop-chemicals industry will continue to consolidate in coming years. It wouldn't be surprised if Nufarm becomes an M&A target. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
April 15, 2026 20:13 ET (00:13 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.